TG THERAPEUTICS, INC. - 8-K Filing
TG Therapeutics announced positive Phase 1 trial results showing that its subcutaneous formulation of ublituximab (BRIUMVI) achieved pharmacokinetic and safety profiles supporting quarterly dosing. The data indicate a mean bioavailability exceeding 60% compared to IV administration, with no new safety signals observed across over 225 injections in more than 80 patients. Top-line results from the ongoing Phase 3 trial are expected by late 2026 or early 2027. (Items: 8.01 Other Events On June 3, 2026, TG Therapeutics, Inc, 9.01 Financial Statements and Exhibits)
Tickers: $TGTX